To update readers on the clinical management of infections secondary to Mycobacterium avium complex (MAC) in patients with AIDS. A general description of the organism, culture and susceptibility testing, and clinical manifestations of the disease is provided. Several aspects of the treatment of the disease, including an historical perspective, current approaches, and future research opportunities, are described.
DATA SOURCES:
Current medical literature, including abstracts presented at international meetings, is reviewed. References were identified through MEDLINE, Current Contents, and published meeting abstracts.
STUDY SELECTION:
Data regarding the epidemiology, clinical manifestations, culture and susceptibility testing, and treatment of MAC are cited. Specific attention is given to the management of patients with MAC infection.
DATA EXTRACTION:
Information contributing to the discussion of the topics selected by the author is reviewed. Data supporting and disputing specific conclusions are presented.
DATA SYNTHESIS:
Disseminated MAC infection is diagnosed antemortem in approximately 30 percent of patients with AIDS; postmortem rates of isolation exceed 50 percent. The incidence of MAC may increase as attempts at isolating the organism become more aggressive. The traditional approach to the isolation, susceptibility testing, and treatment of MAC has been derived from the management of Mycobacterium tuberculosis, with disappointing results. Newer radiometric in vitro methods of susceptibility testing appear to show more promise. Current mouse models of MAC are not true AIDS models; new CD4-deficient mouse models are being developed. Clinical mycobacteriologic and pharmacokinetic laboratory support have been underused, with treatment generally proceeding empirically. New agents that may contribute to the management of disseminated MAC infection include the macrolide derivatives clarithromycin and azithromycin. Research also continues with new rifamycins (including rifabutin) and fluoroquinolones (ciprofloxacin, sparfloxacin). Preliminary results suggest a central role for macrolides in the treatment of disseminated MAC; effective companion drugs are needed to prevent the rapid emergence of macrolide-resistant MAC.
CONCLUSIONS:
Treatment results for disseminated MAC infection remain poor. Therapy may be improved by selecting drugs on the basis of susceptibility data for each isolate, rather than by using empiric regimens based on susceptibility trends. Significant antimycobacterial drug malabsorption has been documented, and may contribute to poor outcomes. More-potent agents are needed to improve the clinical outcome in AIDS patients with MAC.
Get full access to this article
View all access options for this article.
References
1.
SandersWEHorowitzEA. Other mycobacterium species. In: MandellGLDouglasRGBennettJE, eds. Principles and practice of infectious diseases. New York: Churchill Livingstone, 1990:1914–26.
2.
IsemanMDCorpeRFO'BrienRJRosenwiegDYWolinskyE. Disease due to Mycobacterium avium-intracellulare. Chest1985; 87 (suppl):139S–49S.
3.
O'BrienRJ. Pulmonary disease due to Mycobacterium avium complex. Semin Respir Med1988; 9:492–7.
4.
GreeneJBSidhuGSLewinSLevineJFMasurHSimberkoffMS. Mycobacterium avium-intracellulare: A cause of disseminated life-threatening infection in homosexuals and drug abusers. Ann Intern Med1982; 97:539–46.
5.
HorsburghCRJrMasonUGIIIFarhiDCIsemanMD. Disseminated infection with Mycobacterium avium-intracellulare. A report of 13 cases and a review of the literature. Medicine1985; 64:36–48.
6.
KiehnTEEdwardsFFBrannonPTsangAYMaioMGoldJWM. Infections caused by Mycobacterium avium complex in immunocompromised patients: Diagnosis by blood culture and fecal examination, antimicrobial susceptibility tests, and morphological and seroagglutination characteristics. J Clin Microbiol1985; 21:168–73.
7.
WongBEdwardFFKiehnTEWhimbeyEDonnellyHBernardEM. Continuous high-grade Mycobacterium avium-intracellulare bacteremia in patients with the acquired immunodeficiency syndrome. Am J Med1985; 78:35–40.
8.
GlassrothJ. Mycobacterium avium complex in patients with the acquired immune deficiency syndrome. Semin Respir Med1988; 9:486–91.
9.
HorsburghCRSelikRM. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome. Am Rev Respir Dis1989; 139:4–7.
10.
EllnerJJGoldbergerMJParentiDM. Mycobacterium avium infections and AIDS: A therapeutic dilemma in rapid evolution. J Infect Dis1991; 163:1326–35.
11.
HorsburghCR. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med1991; 324:1332–8.
12.
PitchenikAEFertelD. Tuberculosis and nontuberculous mycobacterial disease. Med Clin North Am1992; 76:121–71.
13.
HeifetsLB. Antituberculosis drugs: Antimicrobial activity in vitro. In: HeifetsLB, ed. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press, 1991:13–58.
14.
HeifetsLB. Dilemmas and realities in drug susceptibility testing of M. avium-M. intracellulare and other slowly growing nontuberculous mycobacteria. In: HeifetsLB, ed. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press, 1991:123–46.
15.
HorsburghCRMasonUGHeifetsLBSouthwickKLaBrecqueJFIsemanMD. Response to therapy of pulmonary Mycobacterium avium-intracellulare infection correlates with results of in vitro susceptibility testing. Am Rev Respir Dis1987; 135:418–21.
16.
TsukamuraM. Evidence that antituberculosis drugs are really effective in the treatment of pulmonary infection caused by Mycobacterium avium complex. Am Rev Respir Dis1988; 137:144–8.
17.
CynamonMHKlemensSP. Drug susceptibility test for Mycobacterium fortuitum and Mycobacterium chelonae. In: HeifetsLB, ed. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press, 1991:147–59.
18.
American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am Rev Respir Dis1990; 142:940–53.
19.
MoelleringRC. Principles of anti-infective therapy. In: MandellGLDouglasRGBennettJE, eds. Principles and practice of infectious diseases. New York: Churchill Livingstone, 1990:206–18.
20.
HeifetsLBIsemanMD. Individualized therapy versus standard regimens in the treatment of Mycobacterium avium infections. Am Rev Respir Dis1991; 144:1–2.
21.
HeifetsLBIsemanMD. Choice of antimicrobial agents for M. avium disease based on quantitative tests of drug susceptibility. N Engl J Med1990; 323:419–20.
22.
PeloquinCA. Therapeutic drug monitoring: Principles and applications in mycobacterial infections. Drug Ther1992; 22:31–6.
IsemanMDBuschmanDLAckersonLM. Pectus excavatum and scoliosis. Thoracic anomalies associated with pulmonary disease caused by Mycobacterium avium complex. Am Rev Respir Dis1991; 144:914–6.
25.
CameronWSpartiPPietroskiNPearceDEronLSullmanP. Rifabutin prevents M. avium-complex bacteremia patients with AIDS and CD4 ≤200. Abstract 888, 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1992 Oct 11–14; Anaheim, CA.
26.
GordinFNightengaleSWynneBKaufmanDSchoenfelderJSouderD. Rifabutin monotherapy prevents M. avium-complex bacteremia patients with AIDS. Abstract 889, 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1992 Oct 11–14; Anaheim, CA.
27.
LevinRHBolingerAM. Treatment of nontuberculous mycobacterial infections in pediatric patients. Clin Pharm1988; 7:545–51.
28.
HoyJMijchASandlandMGraysonLLucasRDwyerB. Quadruple-drug therapy for Mycobacterium avium-intracellulare bacteremia in AIDS patients. J Infect Dis1990; 161:801–5.
29.
ChiuJNussbaumJBozzetteSTillesJGYoungLSLeedomJ. Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. Ann Intern Med1990; 113:358–61.
30.
HorsburghCRHavlikJAEllisDAKennedyEFaanSADuboisRE. Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy. Am Rev Respir Dis1991; 144:557–9.
31.
RathburnRCMartinESIIIEatonVEMatthewEB. Current and investigational therapies for AIDS-associated Mycobacterium avium complex disease. Clin Pharm1991; 10:280–91.
32.
KemperCAMengTCNussbaumJChiuJFeigalDFBartokAE. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Ann Intern Med1992; 116:466–72.
33.
HeifetsLB. Drug combinbations. In: HeifetsLB, ed. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press, 1991:179–99.
34.
YoungLSWiviottLWuMLolonoskiPBolanRInterliedCB. Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS. Lancet1991; 338:1107–9.
35.
HeifetsLLindholm-LevyP. Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against M. avium and M. tuberculosis. Antimicrob Agents Chemother1989; 33:1298–301.
36.
LeysenDCHaemersPattynSR. Mycobacteria and the new quinolones. Antimicrob Agents Chemother1989; 33:1–5.
37.
KahanaLMSpinoM. Ciprofloxacin in patients with mycobacterial infections: Experience in 15 patients. DICP Ann Pharmacother1991; 25: 919–24.
38.
DickinsonJMMitchisonDA. In vitro activity of new rifamycins against rifampin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle1987; 68:177–82.
39.
HeifetsLBIsemanMDLindholm-LevyPJ. Combinations of rifampin or rifabutine plus ethambutol against Mycobacterium avium complex. Am Rev Respir Dis1988; 137:711–5.
40.
O'BrienRJLyleMASniderDE. Rifabutin (Ansamycin LM 427): A new rifamycin-S derivative for the treatment of mycobacterial disease. Rev Infect Dis1987; 9:519–30.
41.
SaitoHSatoKTomiokaH. Comparative in vitro and in vivo activity of rifabutin and rifampicin against Mycobacterium avium complex. Tubercle1988; 69:187–92.
42.
SkinnerMHHsiehMTorsethJPauloinDBhatiaGHarkonenS. Pharmacokinetics of rifabutin. Antimicrob Agents Chemother1989; 33:1237–41.
43.
O'BrienRJGeiterLJLyleMA. Rifabutin (Ansamycin LM 427) for the treatment of pulmonary Mycobacterium avium complex. Am Rev Respir Dis1990; 141:821–6.
44.
DautzenbergBTruffotCMignonARozenbaumWKatlamaCPerronneC. Rifabutin in combination with clofazimine, isoniazid, and ethambutol in the treatment of AIDS patients with infections due to opportunistic mycobacteria. Tubercle1991; 72:168–75.
45.
DautzenbergBTruffotCLegrisSMeyohasMCBerlieHCMercatA. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. Am Rev Respir Dis1991; 144:564–9.
46.
BahalNNahataMC. The new macrolide antibiotics: Azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother1992; 26:46–55.
47.
FernandesPBHardyDJMcDanielDHansonCWSwansonRN. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother1989; 33:1531–4.
48.
NaikSRuckR. In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. Antimicrob Agents Chemother1989; 33:1614–6.
49.
RastogiNLabrousseV. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. Antimicrob Agents Chemother1991; 35:462–70.
50.
HeifetsLBLindholm-LevyPJComstockRD. Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium. Am Rev Respir Dis1992; 145:856–8.
51.
DrewRHGallisHA. Azithromycin—spectrum of activity, pharmacokinetics, and clinical applications. Pharmacotherapy1992; 12:161–73.
52.
GordonSHorsburghCRHavlikJHeifetsLPeloquinCMetchockB. Impaired absorption of oral regimen in treatment of disseminated M. avium complex infection. Abstract 896, 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1992 Oct 11–14; Anaheim, CA.
53.
BerningSEHuittGAIsemanMDPeloquinCA. Malabsorption of antituberculosis medications by a patient with AIDS (letter). N Engl J Med1992; 327:1817–8.
54.
BermudezLEWuMYoungLSInterliedCB. Postantibiotic effect of amikacin and rifapentine against Mycobacterium avium complex. J Infect Dis1992; 166:923–6.
55.
ChaissonREBensonCDubeMKorvickJWuALitcherS. Clarithromycin therapy for disseminated Mycobacterium avium-complex (MAC) in AIDS. Abstract 891, 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1992 Oct 11–14; Anaheim, CA.
56.
ZillyWBreimerDDRichterE. Pharmacokinetic interactions with rifampin. Clin Pharmacokinet1977; 2:61–70.
57.
BaciewiczAMSelfTH. Rifampin drug interactions. Arch Intern Med1984; 144:1667–71.
58.
BaciewiczAMSelfTHBekemeyerWB. Update on rifampin drug interactions. Arch Intern Med1987; 147:565–8.
59.
BorcherdingSMBaciewiczAMSelfTH. Update on rifampin drug interactions II. Arch Intern Med1992; 152:711–6.
60.
PeloquinCA. Antituberculosis drugs: Pharmacokinetics. In: HeifetsLB, ed. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press, 1991:59–88.
61.
RadandtJMMarchbanksCRDudleyMN. Interactions of fluoroquinolones with other drugs: Mechanisms, variability, clinical significance, and management. Clin Infect Dis1992; 14:272–84.
62.
ChanGLC. Alternative dosing strategy for aminoglycosides: Impact on efficacy, nephrotoxicity, and ototoxicity. DICP Ann Pharmacother1989; 23:788–94.
PeloquinCBerningSNittaASimoneP. High-dose aminoglycosides for mycobacterial infections. Abstract 4-09, 1992 World Congress on Tuberculosis; 1992 Nov 16–19; Bethesda, MD.
65.
LeBelMSpinoM. Pulse dosing versus continuous infusion of antibiotics. Pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet1988; 14:71–95.
66.
PeloquinCACumboTJNixDESandsMFSchentagJJ. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch Intern Med1989; 149:2269–73.
